NICE backs Medtronic's AF monitor in post-stroke patients

England’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data to doctors remotely, which is recommended for funding following draft gui

AZ axes phase 3 heart disease trial of fish oil drug Epanova

AstraZeneca has axed a large late-stage trial for its heart disease drug Epanova in patients with mixed dyslipidemia (MDL), and expects to write off at least $100 million from its profits i

AZ and Novoheart collaborate on 'heart in a jar', to develop...

Stem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will be used to help develop new heart failure drugs.

Novartis eyes $5bn The Medicines Company acquisition - repor...

Novartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for a deal that could expand its pipeline of cardiac medicines, according to p

Amgen pulls higher-priced Repatha to try to lift sales

FDA approves AZ's Farxiga in new heart failure prevention us...

The FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in adults with type 2 diabetes and other cardiovascular risks.<